Skip to main content
ONCOLYTICS BIOTECH INC logo

ONCOLYTICS BIOTECH INC — Investor Relations & Filings

Ticker · ONCY ISIN · CA6823108759 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2026-06-02 Board/Management Inform…
Country US United States of America
Listing US ONCY

About ONCOLYTICS BIOTECH INC

https://www.oncolyticsbiotech.com/

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immuno-oncolytic virus. This immunotherapeutic agent is designed to selectively replicate in cancer cells, which triggers innate and adaptive anti-tumor immune responses. By awakening the patient's immune system, pelareorep aims to enhance the efficacy of other oncology treatments, such as chemotherapy and immune checkpoint inhibitors. The company's clinical development program is evaluating its potential across various cancer types, with a focus on HR+/HER2- breast cancer and pancreatic cancer, where it has demonstrated the potential to extend survival times and reduce tumor burden.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 94% confidence The document is a Form 8-K "Current Report" filed pursuant to the Securities Exchange Act of 1934, and specifically Item 5.02 and 5.02 (Departure/Election of Directors or Certain Officers) detailing the appointment of a new executive officer and a new board director. This is a direct announcement of changes in the company’s senior management and board, fitting the Board/Management Information category.
2026-06-02 English
8-K
Regulatory Filings Classification · 85% confidence The document is an SEC Form 8-K “Current Report” disclosing “Other Events” (a press release issuance) and exhibits, without containing substantive financial statements or directing shareholders to vote. It is a general regulatory filing rather than an annual or interim report, earnings release, management discussion, or specific notice type. Thus, it falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-06-01 English
8-K
Regulatory Filings Classification · 88% confidence The document is a Form 8-K (Current Report) filed under the Securities Exchange Act of 1934, disclosing Item 8.01 “Other Events” and attaching a press release as an exhibit. It is a routine SEC regulatory filing and does not itself constitute a full financial or annual report, management discussion, earnings release, or any other specialized disclosure category. Therefore, it falls under the fallback “Regulatory Filings” category (RNS).
2026-05-22 English
8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” filed under Section 13/15(d) of the Exchange Act, reporting an “Other Events” press release attached as an exhibit. It does not themselves present earnings or full financial statements, nor details of management changes or M&A activity. As a generic regulatory announcement/report filing, it falls under the Regulatory Filings category (RNS).
2026-05-04 English
8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Oncolytics Biotech has aligned with the FDA on the design of a pivotal clinical study for a cancer drug. It discusses regulatory interactions, study design, and clinical trial plans but does not contain any financial data, earnings, or detailed report content. It is not an annual or interim report, audit, or earnings release. It is an update on regulatory and clinical development progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2026-04-27 English
8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions an "Other Events" section describing a press release about an upcoming FDA meeting and includes the press release as an exhibit. The document length is 3386 characters, which is relatively short and mainly serves as an announcement rather than a detailed report. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, earnings release, or management discussion. It is primarily a regulatory filing to inform investors of a material event. Therefore, it fits best under Regulatory Filings (RNS).
2026-04-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.